头孢洛扎/他唑巴坦用于治疗儿童囊性纤维化急性加重：现有数据综述
Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to : A Review of Available Data.
作者信息
Garazzino Silvia, Altieri Elena, Silvestro Erika, Pruccoli Giulia, Scolfaro Carlo, Bignamini Elisabetta
机构信息
Department of Child Pathology and Treatment "Regina Margherita", Unit of Infectious Diseases, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy.
Postgraduate School of Pediatrics, University of Turin, Turin, Italy.
出版信息
Front Pediatr. 2020 May 5;8:173. doi: 10.3389/fped.2020.00173. eCollection 2020.
Abstract
Ceftolozane-tazobactam is a novel fifth-generation cephalosporin/β-lactamase inhibitor combination recently approved for treatment of both complicated intra-abdominal and urinary tract infections in adults. Considering its potent bactericidal activity against , it might represent an important option also for treating children with exacerbations of cystic fibrosis due to when other alternative treatments have been exhausted. We hereby review available data on the use of ceftolozane-tazobactam in children, focusing on cystic fibrosis.
摘要
头孢洛扎-他唑巴坦是一种新型的第五代头孢菌素/β-内酰胺酶抑制剂组合，最近被批准用于治疗成人复杂性腹腔内感染和尿路感染。鉴于其对……具有强大的杀菌活性，当其他替代治疗方法都已用尽时，它可能也是治疗因……而病情加重的囊性纤维化儿童的一个重要选择。我们在此回顾关于头孢洛扎-他唑巴坦在儿童中使用的现有数据，重点关注囊性纤维化。
相似文献
1
Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to : A Review of Available Data.头孢洛扎/他唑巴坦用于治疗儿童囊性纤维化急性加重：现有数据综述
Front Pediatr. 2020 May 5;8:173. doi: 10.3389/fped.2020.00173. eCollection 2020.
2
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.成功使用头孢洛扎/他唑巴坦治疗由多重耐药铜绿假单胞菌引起的囊性纤维化肺部加重期
Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1.
3
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.囊性纤维化患儿头孢洛扎/他唑巴坦的血浆药代动力学。
Pediatr Pulmonol. 2020 Aug;55(8):2025-2032. doi: 10.1002/ppul.24815. Epub 2020 May 18.
4
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.体外研究头孢洛扎/他唑巴坦对成人囊性纤维化铜绿假单胞菌和其他非发酵革兰阴性菌的抗菌活性。
J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.
5
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.评价头孢洛扎他唑巴坦与其他抗菌药物体外抗囊性纤维化患者铜绿假单胞菌分离株的活性。
Diagn Microbiol Infect Dis. 2019 Jul;94(3):297-303. doi: 10.1016/j.diagmicrobio.2019.01.012. Epub 2019 Jan 27.
6
Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.头孢洛扎/他唑巴坦：治疗复杂性腹腔内和尿路感染的综述。
Drugs. 2016 Feb;76(2):231-42. doi: 10.1007/s40265-015-0524-5.
7
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合
Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1.
8
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.头孢托罗-他唑巴坦用于复杂性尿路感染和腹腔内感染的批判性评价。
Ther Clin Risk Manag. 2016 May 19;12:787-97. doi: 10.2147/TCRM.S83844. eCollection 2016.
9
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
10
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦：一种新型头孢菌素与β-内酰胺酶抑制剂的组合。
Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9.
引用本文的文献
1
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.用于治疗儿童多重耐药革兰氏阴性菌感染的新型β-内酰胺类抗生素：一项叙述性综述
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
2
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.头孢洛扎他唑巴坦对囊性纤维化临床分离的铜绿假单胞菌在中空纤维感染模型中的作用：高突变率和异质性耐药带来的挑战。
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10.
3
Antimicrobial Treatment of Severe Sepsis.严重脓毒症的抗菌治疗
Antibiotics (Basel). 2022 Oct 18;11(10):1432. doi: 10.3390/antibiotics11101432.
4
Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.耐多药铜绿假单胞菌分离株的抗生素耐药趋势及联合药敏检测：10 年更新。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02483-20.
本文引用的文献
1
Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments.抗生素组合对抗自动化时间 lapse 显微镜和静态杀菌实验中的多重耐药铜绿假单胞菌的疗效。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.02111-19.
2
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.头孢他啶阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界经验
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02291-19.
3
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.头孢洛扎/他唑巴坦治疗难治性铜绿假单胞菌感染：对其治疗适应证外的疗效和安全性的系统评价。
Int J Antimicrob Agents. 2020 Mar;55(3):105891. doi: 10.1016/j.ijantimicag.2020.105891. Epub 2020 Jan 8.
4
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.头孢洛扎/他唑巴坦在新生儿和婴幼儿中的应用：在这一脆弱患者群体中收集药代动力学和安全性数据的挑战。
Am J Perinatol. 2021 Jul;38(8):804-809. doi: 10.1055/s-0039-3402719. Epub 2020 Jan 7.
5
A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.妥布霉素二聚体而非单体增强头孢洛扎治疗多重耐药和广泛耐药铜绿假单胞菌的作用，并延缓耐药性的产生。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02055-19.
6
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Treated With Ceftolozane/Tazobactam.较高的最低抑菌浓度（>2mg/L）可预测接受头孢洛扎/他唑巴坦治疗的耐多药和广泛耐药性引起的下呼吸道感染患者的30天死亡率。
Open Forum Infect Dis. 2019 Sep 28;6(10):ofz416. doi: 10.1093/ofid/ofz416. eCollection 2019 Oct.
7
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.头孢洛扎/他唑巴坦对全球监测项目中 2015-2017 年分离的当代铜绿假单胞菌的抗菌活性。
J Glob Antimicrob Resist. 2020 Jun;21:60-64. doi: 10.1016/j.jgar.2019.10.009. Epub 2019 Oct 21.
8
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.体外研究头孢洛扎他唑巴坦和头孢他啶-阿维巴坦对耐美罗培南铜绿假单胞菌临床分离株的活性：一项多中心研究。
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
9
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.头孢洛扎他唑巴坦与美罗培南治疗医院获得性肺炎（ASPECT-NP）：一项随机、对照、双盲、3 期、非劣效性试验。
Lancet Infect Dis. 2019 Dec;19(12):1299-1311. doi: 10.1016/S1473-3099(19)30403-7. Epub 2019 Sep 25.
10
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.在囊性纤维化患者中使用连续输注头孢他啶-他唑巴坦并进行治疗药物监测。
Am J Health Syst Pharm. 2019 Apr 8;76(8):501-504. doi: 10.1093/ajhp/zxz011.
Zotero 插件